Head-to-head · WeighScore
Fridays vs G-Plans
The verdict
Too close to call — both grade 53.8/100 (C).
Fridays and G-Plans land on the same WeighScore, so neither clears the other on our six graded dimensions. Fridays sits one line higher on the board (#461 vs #462) on the underlying tiebreak, but it's a genuine coin-flip — pick on the factors and prices that matter most to you below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Fridays | G-Plans |
|---|---|---|
| WeighScore | 53.8/100 | 53.8/100 |
| Grade | C | C |
| Scorecard rank | #461 | #462 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #461 · C
Strengths
- Both semaglutide and tirzepatide available
Where it loses points
- Pricing not publicly disclosed
Graded #462 · C
Strengths
- Both semaglutide and tirzepatide available
Where it loses points
- Pricing not publicly disclosed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.